Interleukin-8 T-251A polymorphism was associated with positive anti-p53 antibodies in Uzbekistan population.

Interleukin (IL)-8, a proinflammatory chemokine, has been reported to have angiogenic activity and to be responsible for tumor-associated angiogenesis in several cancers. The polymorphism IL-8 T-251A (rs4073) is known to be associated with the expression of IL-8 protein and is related to several cancers. A serum anti-p53 antibody, a new tumor marker, increases in accordance with the mutation of tumor suppressor gene p53. Previous studies have reported the association between IL-8 and p53 mutation in cancer cells or tissues. Therefore, we hypothesized that IL-8 polymorphism might be associated with serum anti-p53 antibody levels. Study subjects were 197 participants (103 males and 94 females, aged 15 to 56 years) who were enrolled in a case-control study on peptic ulcer disease from January to March 2007 in the Uzbekistan Republic. Serum anti-p53 antibody, CEA, and CA19-9 levels were measured, and IL-8 T-251A was genotyped. The A allele frequency in control subjects was 0.48, which is close to the previous reports for Caucasian populations. The proportion of subjects with positive anti-p53 antibodies (higher than 1.3 U/ mL) was greater for AA genotype carriers compared to T allele carriers (17% for AA, and 6% for TA+TT; OR 3.4, p = 0.025 after adjusting for age, sex, comorbidity and ethnicity). Such a difference was not observed for either CEA or CA19-9. We demonstrated that the IL-8 -251 AA genotype was associated with higher anti-p53 antibodies than those of the reference range. Further studies are warranted to clarify whether those with this genotype carrier are susceptible to malignant diseases.